FY2025 EPS Forecast for Medicus Pharma Boosted by Analyst

Medicus Pharma Ltd. (NASDAQ:MDCXFree Report) – Equities research analysts at Brookline Capital Management boosted their FY2025 earnings per share estimates for shares of Medicus Pharma in a report released on Tuesday, April 8th. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($0.88) per share for the year, up from their previous estimate of ($1.53). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Management also issued estimates for Medicus Pharma’s FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at $0.44 EPS.

Medicus Pharma (NASDAQ:MDCXGet Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14.

Separately, Maxim Group began coverage on Medicus Pharma in a research note on Tuesday, December 17th. They issued a “buy” rating and a $10.00 price target for the company.

Get Our Latest Analysis on MDCX

Medicus Pharma Price Performance

Shares of Medicus Pharma stock opened at $3.58 on Friday. The stock has a 50-day moving average price of $3.44. Medicus Pharma has a fifty-two week low of $1.80 and a fifty-two week high of $6.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCXFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma accounts for 1.3% of Interchange Capital Partners LLC’s portfolio, making the stock its 15th largest position. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma at the end of the most recent quarter.

Medicus Pharma Company Profile

(Get Free Report)

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Read More

Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.